These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 24427838

  • 1. Thrombotic risk of contraceptive transdermal patches and the contraceptive vaginal ring.
    Prescrire Int; 2013 Nov; 22(143):266, 268-9. PubMed ID: 24427838
    [Abstract] [Full Text] [Related]

  • 2. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
    Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E.
    BMJ; 2012 May 10; 344():e2990. PubMed ID: 22577198
    [Abstract] [Full Text] [Related]

  • 3. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug 10; 13(72):123-6. PubMed ID: 15532134
    [Abstract] [Full Text] [Related]

  • 4. Drospirenone: more cases of thrombosis than with levonorgestrel.
    Prescrire Int; 2013 Nov 10; 22(143):267. PubMed ID: 24427839
    [Abstract] [Full Text] [Related]

  • 5. Drospirenone: high risk of venous thrombosis.
    Prescrire Int; 2011 Feb 10; 20(113):43-5. PubMed ID: 21488592
    [Abstract] [Full Text] [Related]

  • 6. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study.
    Fleischer K, van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM.
    Thromb Res; 2009 Feb 10; 123(3):429-35. PubMed ID: 18829069
    [Abstract] [Full Text] [Related]

  • 7. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors.
    Tanis BC, Rosendaal FR.
    Semin Vasc Med; 2003 Feb 10; 3(1):69-84. PubMed ID: 15199494
    [Abstract] [Full Text] [Related]

  • 8. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS, Jick H.
    Contraception; 2006 Oct 10; 74(4):290-2. PubMed ID: 16982227
    [Abstract] [Full Text] [Related]

  • 9. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
    Cole JA, Norman H, Doherty M, Walker AM.
    Obstet Gynecol; 2007 Feb 10; 109(2 Pt 1):339-46. PubMed ID: 17267834
    [Abstract] [Full Text] [Related]

  • 10. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives.
    Raps M, Helmerhorst F, Fleischer K, Thomassen S, Rosendaal F, Rosing J, Ballieux B, VAN Vliet H.
    J Thromb Haemost; 2012 Jun 10; 10(6):992-7. PubMed ID: 22469296
    [Abstract] [Full Text] [Related]

  • 11. Hormonal contraception, thrombosis and age.
    Lidegaard Ø.
    Expert Opin Drug Saf; 2014 Oct 10; 13(10):1353-60. PubMed ID: 25227335
    [Abstract] [Full Text] [Related]

  • 12. Ethinylestradiol + etonogestrel contraceptive vaginal ring: new drug. Possibly useful in some situations.
    Prescrire Int; 2006 Apr 10; 15(82):50-3. PubMed ID: 16604729
    [Abstract] [Full Text] [Related]

  • 13. Innovations in contraception: a review.
    Zurawin RK, Ayensu-Coker L.
    Clin Obstet Gynecol; 2007 Jun 10; 50(2):425-39. PubMed ID: 17513928
    [Abstract] [Full Text] [Related]

  • 14. Combined hormonal contraception and venous thromboembolism.
    Martínez F, Avecilla A.
    Eur J Contracept Reprod Health Care; 2007 Jun 10; 12(2):97-106. PubMed ID: 17559006
    [Abstract] [Full Text] [Related]

  • 15. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S, Kaye JA, Li L, Jick H.
    Contraception; 2007 Jul 10; 76(1):4-7. PubMed ID: 17586129
    [Abstract] [Full Text] [Related]

  • 16. The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study.
    Hannaford PC, Kay CR.
    Br J Gen Pract; 1998 Oct 10; 48(435):1657-62. PubMed ID: 10071398
    [Abstract] [Full Text] [Related]

  • 17. Does switching contraceptive from oral to a patch or vaginal ring change the likelihood of timely prescription refill?
    Law A, Lee YC, Gorritz M, Plouffe L.
    Contraception; 2014 Aug 10; 90(2):188-94. PubMed ID: 24835829
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of estrogen-induced venous thromboembolism.
    Tchaikovski SN, Rosing J.
    Thromb Res; 2010 Jul 10; 126(1):5-11. PubMed ID: 20163835
    [Abstract] [Full Text] [Related]

  • 19. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.
    Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP, Cooper WO.
    Contraception; 2013 Jan 10; 87(1):93-100. PubMed ID: 23083525
    [Abstract] [Full Text] [Related]

  • 20. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study.
    Piltonen T, Puurunen J, Hedberg P, Ruokonen A, Mutt SJ, Herzig KH, Nissinen A, Morin-Papunen L, Tapanainen JS.
    Hum Reprod; 2012 Oct 10; 27(10):3046-56. PubMed ID: 22811306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.